Tejas Savant
Stock Analyst at Morgan Stanley
(2.26)
# 1,463
Out of 4,502 analysts
171
Total ratings
41.86%
Success rate
-3.8%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $280 | $232.29 | +20.54% | 9 | Jul 23, 2024 | |
| TEM Tempus AI | Initiates: Overweight | $44 | $40.02 | +9.95% | 1 | Jul 9, 2024 | |
| AKYA Akoya Biosciences | Maintains: Overweight | $8 → $4 | $2.44 | +63.93% | 9 | Jun 3, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Equal-Weight | $10 → $4 | $1.91 | +109.97% | 7 | May 15, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Equal-Weight | $2 → $1 | $0.34 | +197.09% | 2 | May 15, 2024 | |
| VCYT Veracyte | Maintains: Underweight | $22 → $21 | $23.76 | -11.62% | 7 | Feb 26, 2024 | |
| HOLX Hologic | Maintains: Equal-Weight | $86 → $82 | $77.88 | +5.29% | 7 | Nov 13, 2023 | |
| NTRA Natera | Maintains: Overweight | $70 → $68 | $102.15 | -33.43% | 7 | Nov 10, 2023 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Overweight | $12 → $11 | $8.51 | +29.26% | 10 | Nov 9, 2023 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $8 → $7 | $6.50 | +7.69% | 8 | Nov 9, 2023 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $16 → $17 | $15.08 | +12.73% | 11 | Nov 8, 2023 | |
| AVTR Avantor | Maintains: Overweight | $24 → $22 | $22.82 | -3.59% | 12 | Oct 30, 2023 | |
| TMO Thermo Fisher | Maintains: Overweight | $600 → $545 | $594.50 | -8.33% | 9 | Oct 26, 2023 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $13 → $10 | $4.33 | +130.95% | 9 | Oct 24, 2023 | |
| CTLT Catalent | Maintains: Overweight | $52 → $55 | $58.45 | -5.90% | 10 | Aug 30, 2023 | |
| CYRX Cryoport | Initiates: Equal-Weight | $16 | $8.96 | +78.57% | 1 | Aug 17, 2023 | |
| TXG 10x Genomics | Reiterates: Overweight | $65 | $19.92 | +226.31% | 8 | Aug 7, 2023 | |
| NAUT Nautilus Biotechnology | Reiterates: Equal-Weight | $6 | $2.88 | +108.33% | 3 | Aug 3, 2023 | |
| SOPH SOPHiA GENETICS | Maintains: Overweight | $11 → $10 | $4.63 | +115.98% | 8 | May 10, 2023 | |
| RPID Rapid Micro Biosystems | Reiterates: Equal-Weight | $2.75 | $0.69 | +301.46% | 5 | Mar 7, 2023 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $5 | $2.86 | +74.83% | 4 | Feb 27, 2023 | |
| SEER Seer, Inc. | Maintains: Equal-Weight | $11 → $10 | $2.06 | +385.44% | 9 | Feb 21, 2023 | |
| GH Guardant Health | Maintains: Overweight | $80 → $73 | $31.93 | +128.63% | 7 | Feb 21, 2023 | |
| ILMN Illumina | Maintains: Equal-Weight | $240 → $225 | $117.30 | +91.82% | 4 | Nov 7, 2022 | |
| CRL Charles River Laboratories International | Downgrades: Equal-Weight | $350 → $250 | $221.81 | +12.71% | 1 | Aug 4, 2022 | |
| BDSX Biodesix | Maintains: Equal-Weight | $7 → $5 | $1.66 | +201.20% | 3 | May 12, 2022 |
IQVIA Holdings
Jul 23, 2024
Maintains: Overweight
Price Target: $270 → $280
Current: $232.29
Upside: +20.54%
Tempus AI
Jul 9, 2024
Initiates: Overweight
Price Target: $44
Current: $40.02
Upside: +9.95%
Akoya Biosciences
Jun 3, 2024
Maintains: Overweight
Price Target: $8 → $4
Current: $2.44
Upside: +63.93%
Pacific Biosciences of California
May 15, 2024
Maintains: Equal-Weight
Price Target: $10 → $4
Current: $1.91
Upside: +109.97%
Ginkgo Bioworks Holdings
May 15, 2024
Maintains: Equal-Weight
Price Target: $2 → $1
Current: $0.34
Upside: +197.09%
Veracyte
Feb 26, 2024
Maintains: Underweight
Price Target: $22 → $21
Current: $23.76
Upside: -11.62%
Hologic
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $86 → $82
Current: $77.88
Upside: +5.29%
Natera
Nov 10, 2023
Maintains: Overweight
Price Target: $70 → $68
Current: $102.15
Upside: -33.43%
Maravai LifeSciences Holdings
Nov 9, 2023
Maintains: Overweight
Price Target: $12 → $11
Current: $8.51
Upside: +29.26%
Cytek Biosciences
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $6.50
Upside: +7.69%
NeoGenomics
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $15.08
Upside: +12.73%
Avantor
Oct 30, 2023
Maintains: Overweight
Price Target: $24 → $22
Current: $22.82
Upside: -3.59%
Thermo Fisher
Oct 26, 2023
Maintains: Overweight
Price Target: $600 → $545
Current: $594.50
Upside: -8.33%
Adaptive Biotechnologies
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $4.33
Upside: +130.95%
Catalent
Aug 30, 2023
Maintains: Overweight
Price Target: $52 → $55
Current: $58.45
Upside: -5.90%
Cryoport
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $8.96
Upside: +78.57%
10x Genomics
Aug 7, 2023
Reiterates: Overweight
Price Target: $65
Current: $19.92
Upside: +226.31%
Nautilus Biotechnology
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.88
Upside: +108.33%
SOPHiA GENETICS
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.63
Upside: +115.98%
Rapid Micro Biosystems
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $0.69
Upside: +301.46%
Personalis
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $2.86
Upside: +74.83%
Seer, Inc.
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.06
Upside: +385.44%
Guardant Health
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $31.93
Upside: +128.63%
Illumina
Nov 7, 2022
Maintains: Equal-Weight
Price Target: $240 → $225
Current: $117.30
Upside: +91.82%
Charles River Laboratories International
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $221.81
Upside: +12.71%
Biodesix
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.66
Upside: +201.20%